Replimune (REPL) Group announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology, ESMO, Congress 2025 being held in Berlin. The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% with a median duration of response of 11.9 months. The safety profile was favorable with generally transient grade 1 and 2 treatment related adverse events.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Replimune downgraded to Underweight from Neutral at JPMorgan
- Replimune Group Completes FDA Meeting on RP1 Application
- Replimune says ‘committed’ to working with FDA to determine path forward for RP1
- Replimune Group Schedules Crucial FDA Meeting for RP1